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Introduction: Bordetella petrii is an emerging pathogen. Whilst association with cystic fibrosis
(CF) has been described previously, this is the first report to our knowledge of multidrug-resistant
B. petrii incidence in an Irish CF patient population.
Case presentation: Using a case series of four adult CF patients with varying baselines of
health, one of whom was asymptomatic, this report attempts correlation of B. petrii colonization,
by one common strain, with incidence of acute exacerbation of symptoms. As definitive
guidelines for antimicrobial sensitivity/resistance do not exist for B. petrii, we completed a
systematic review of available literature to collate evidence of antimicrobial efficacy against
B. petrii. Comparison with the isolates in this study indicated B. petrii sensitivity to piperacillin/
tazobactam and minocycline but resistance to antimicrobials in the macrolide, other b-lactam and
fluoroquinolone groups.
Conclusion: To our knowledge, this is the first report of multiple CF patients sharing a strain of
B. petrii. Furthermore, B. petrii may be under-identified in CF patients and should be considered
when evaluating exacerbation of CF symptoms.
Keywords: Bordetella colonization; cystic fibrosis; multidrug-resistant.
Introduction
Bordetella petrii is unique among Bordetella species as it is
capable of independent existence as an environmental
facultative anaerobe (Gross et al., 2008). Most of the nine
Bordetella species are host restricted. B. pertussis, B.
parapertussuis, B. holmesii, B. ansorpii, B. hinzii and B.
trematum are human pathogens (Mattoo and Cherry,
2005; Fry et al., 2007a, b; Ko et al., 2005; Gerlach et al.,
2001; Moissenet et al., 2011; Livovsky et al., 2012). B.
bronchiseptica causes disease in mammals and B. avium in
birds specifically (Gerlach et al., 2001).
Studies of B. petrii are comprised largely of molecular
characterization (typically of environmental isolates)
(Gross et al., 2010; Zelazny et al., 2013). However, there
are a limited number of descriptions involving clinical
incidences: mandibular osteomyelitis (Fry et al., 2005),
suppurative mastoiditis (Stark et al., 2007) and respiratory
infections particularly in patients with bronchiectasis (Le
Coustumier et al., 2011) and cystic fibrosis (CF) (Spilker et
al., 2008).
Globally, Ireland has the highest prevalence of CF (a
recessive autosomal disease associated with increased
susceptibility to respiratory infection) with a prevalence
of 2.98 per 10 000 of the population compared with
prevalence in Europe and the USA of 0.737 and 0.797 per
10 000, respectively (Farrell, 2008). Bordetella species have
Abbreviations: bd, twice day21; i.v., intravenously; MRSA, meticillin-
resistant Staphylococcus aureus; MSSA, meticillin-sensitive S. aureus;
od, once day21; p.o., by mouth; tds, three times day21.
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been associated with CF, with B. petrii in particular being
the species commonly cultured in the sputum of these
patients (Spilker et al., 2008). However, the clinical
significance of B. petrii in CF is unknown. In this report,
using a case series of adult CF patients colonized by a
single discrete strain of B. petrii and with varying baselines
of health (one of whom was asymptomatic), we aimed to
correlate colonization with incidence of acute exacerbation
of symptoms. In addition, as definitive guidelines for
antimicrobial sensitivity/resistance do not exist for B.
petrii, we completed a systematic review of the available
literature to collate evidence of antimicrobial efficacy
against B. petrii and compared this information with the
characteristics of the isolate obtained from the four
patients in this study with a view to determining effective
antimicrobial therapy.
Case report
Four CF patients (three female, mean age 21 years, non-
smokers), named A–D, with chronic B. petrii colonization
were identified in University Hospital, Limerick, Ireland,
between March 2009 and December 2012. Retrospective
analyses of patient charts and stored sputum samples
determined the frequency of hospitalization, episodes of
infections, antimicrobial use and patient quality of life
scores (Henry et al., 2003) for the year prior to B. petrii
detection and throughout colonization. Emphasis was
placed on the presence/absence of clinical features during
colonization, in particular lung function, efficacy of
antimicrobial therapy and patient outcome.
Genotypically, patients A and B were heterozygotic for the
Df508 mutation (within the CF transmembrane conduc-
tance regulator causing loss of the amino acid phenylala-
nine, affecting chloride ion channels in cell membranes and
leading to production of thickened mucus), whilst patients
C and D were homozygous. All resided in the same county
in the midwest of Ireland. Each of the patients had
experienced at least one acute hospitalization in the year
prior to B. petrii detection. As they attended the same
outpatient clinic, exposure to one another was possible. The
clinic implements a system of segregated clinics according to
pathogen status [in particular for Burkholderia cepacia
complex, Pseudomonas aeruginosa and meticillin-resistant
Staphylococcus aureus (MRSA)]. Each clinic uses single-
patient rooms, with healthcare workers rotating through
these (i.e. patients remain in situ to limit cross-transmission
of micro-organisms through contact with other patients,
and the healthcare workers adopt strict infection control
practices during patient contact). However, in 2003,
patients A and D were admitted simultaneously to the
same paediatric ward for 1 day. Also in 2008, patients A and
C were hospitalized simultaneously but in separate wards. B.
petrii was initially detected in March 2009.
B. petrii from sputum was preliminarily reported as an
undetermined Bordetella species. Subsequent identification
of isolates from the four patients was by PCR 16S rRNA
gene sequencing and gyrB sequence cluster analysis, PFGE
and matrix-assisted laser desorption/ionization-time of
flight techniques, and indicated the presence of a single
discrete B. petrii strain. Our group has found that PFGE is
capable of differentiating among B. petrii isolates (data not
shown). Currently, there is no definitive classification of B.
petrii as sensitive/resistant to specific antimicrobials. In this
study, the efficacy of selected antimicrobials against the B.
petrii isolates (subsequently found to be a single strain) was
assessed using Etest (bioMe´rieux) strips.
Patients A, B, C and D first presented with B. petrii in
March 2009, March 2010, January 2011 and February 2011,
respectively. Durations of intermittent colonization ranged
from 8 to 35 months (Table 1). Monomicrobial culture of
B. petrii was relatively infrequent, with P. aeruginosa being
the most common co-isolate, although meticillin-sensitive
S. aureus (MSSA) was found occasionally in three of the
four patients, as were Candida species (Table 1). Notably,
three of the four patients (A, C and D) experienced at least
one acute infective exacerbation of CF while simulta-
neously being positive for B. petrii. These patients were
treated with antimicrobials directly following detection of
B. petrii. Patient B was neither admitted to hospital nor
treated for infective exacerbation during the course of B.
petrii colonization. Retrospective analysis of spirometry
results for all four patients failed to indicate a correlation
between B. petrii detection and impaired lung function
[measured as forced expiratory volume in 1 s (FEV1)].
In patient A, B. petrii was first co-isolated with Aspergillus
fumigatus. Ten days later, the patient required antimicro-
bial therapy at home [piperacillin/tazobactam, 4.5 g three
times day21 (tds) intravenously (i.v.)], nebulized colomy-
cin [2 million units twice day21 (bd)] and clarithromycin
[500 mg bd by mouth (p.o.)]. Subsequently, B. petrii was
not detected for 10 months until February 2010 when B.
petrii re-occurred as a monomicrobial isolate. Patient A
was treated with nebulized colomycin (as above) and a
3 week course of oral ciprofloxacin (500 mg bd). In April
2010, treatment for P. aeruginosa was nebulized colomycin
(as above) and meropenem (2 g tds i.v.), and in May 2010,
B. petrii was detected for the third time. Aspergillus
fumigatus was also present. At that time, the patient
presented with a 3-day history of haemoptysis and
increased volume of sputum. A chest X-ray showed patchy
infiltrates. Successful treatment consisted of 2 weeks of
nebulized colomycin (as above) and meropenem (as
above) and switch therapy with oral co-amoxiclav
(625 mg tds). In August 2010 and April 2011, B. petrii
was again detected, although the patient was asymptomatic
on both occasions. B. petrii was not detected again until
December 2011 but now persisted concomitantly with
Achromobacter xylosoxidans and Aspergillus fumigatus.
In patient B, following first detection, B. petrii was
identified in 12 of the subsequent 13 sputum samples
tested (92 %). Nine of these were polymicrobial, and only
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one with P. aeruginosa. Other co-colonizers included
Candida spp., MSSA, Cupriavidus metallidurans,
Alcaligenes faecalis and Achromobacter xylosoxidans. No
respiratory symptoms were reported and therefore no
antimicrobial treatment was offered.
In contrast, patient C was positive for B. petrii on only 3 of
13 samplings (23 %) since first detection. On each occasion,
P. aeruginosa was also identified, and the patient required
treatment for infective exacerbation of CF. In January 2011,
treatment comprised tobramycin [10 mg kg21 once day21
(od) i.v.] (dependent on trough levels), flucloxacillin [2 g
four times day21 (qds) i.v.] and piperacillin/tazobactam
(4.5 g tds i.v.), which effectively eradicated B. petrii until
June 2011, at which time P. aeruginosa was also cultured.
The patient was admitted for 4 days of i.v. hydrocortisone
treatment with a course of ciprofloxacin (500 mg bd p.o.).
However, the patient clinically deteriorated after cessation
of treatment and merited further antimicrobials for 2 weeks
in July: a repeat course of ciprofloxacin (as above) with
linezolid (600 mg bd p.o.). In August 2011, patient C was
again admitted for acute infective exacerbation coinciding
with B. petrii, P. aeruginosa and MRSA being isolated from
the sputum. Symptoms included a history of 6 kg weight
loss over the prior 5 weeks, 2 weeks of shortness of breath at
rest, a productive cough with yellow sputum and pyrexia.
Treatment comprised ceftazidime (2 g tds i.v.) for 7 days,
teicoplanin (6 mg kg21 i.v.) for 8 days following double
dosage for the first 24 h and tobramycin (10 mg kg21 od
i.v.) (dependent on trough levels) for 11 days, followed by
nebulized colomycin (2 million units bd) and 6 days of
meropenem (2 g tds i.v.). On discharge, patient C required
ventilatory support, but B. petrii had been effectively
eradicated.
Patient D was admitted due to acute infective exacerba-
tions of CF in May, September and November 2011
coinciding with detection of monomicrobial B. petrii.
Antimicrobial treatment in May comprised meropenem
(2 g tds i.v.), tobramycin (10 mg kg21 od i.v.) (dependent
on trough levels) and linezolid (600 mg bd p.o.); the latter
was cycled with flucloxacillin (2 g qds i.v.) plus merope-
nem (as above) and tobramycin (as above) for the
subsequent exacerbation in September. During the hospi-
talization in December 2011, patient D developed a right
pneumothorax (.50 %). Eight days later, additional
antimicrobials were administered, specifically, vancomycin
(15 mg kg21 bd i.v.), piperacillin/tazobactam (4.5 g tds
i.v.) and azithromycin (500 mg od p.o.) with ciprofloxacin
(500 mg bd p.o.) to treat B. petrii, P. aeruginosa and
Candida sp. These proved ineffective, and 4 days later,
patient D died due to cardiorespiratory failure.
Table 1. Summary of information from patients A–D of the case series
Characteristics Patient A Patient B Patient C Patient D
Outpatient mean %
predicted FEV1
78 % 60 % 37 % 49 %
Inpatient average %
predicted FEV1
66 % – 31 % 43 %
Number of admissions 1/year (2008–2010) 1/year (2009–2011) 3/year (2010–2011) 2/year (2010)
2/year (2011) 4/year (2011)
First diagnosed with B.
petrii
Mar 2009 Mar 2010 Jan 2011 Feb 2011
Number of positive
specimens
8/28 12/13 3/13 8/8
Last sputum sample with
B. petrii
Feb 2012 Jan 2012 Aug 2011 Dec 2011
Duration of Infection 35 months 22 months 8 months 10 months
Number of polymicrobial
B. petrii isolates
7 9 13 7
Main co-colonizers P. aeruginosa, Aspergillus
fumigatus, Candida
spp., Achromobacter
xylosoxidans
P. aeruginosa, Candida
spp, MSSA, Cupriavidus
metallidurans,
Alcaligenes faecalis,
Achromobacter
xylosoxidans
P. aeruginosa, MSSA,
MRSA
P. aeruginosa, MSSA,
Haemophilus
parainfluenzae, Candida
spp.
Number of P. aeruginosa
isolates
1 1 3 3
Number of
monomicrobial cultures
1 3 0 1
Symptoms with
monomicrobial culture
Yes No No Yes
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Discussion
Since its discovery in 2001 (von Wintzingerode et al.,
2001), publications relating to B. petrii have focused largely
on the molecular and biochemical aspects of the organism
(Zelazny et al., 2013). A systematic PubMed search
[‘Bordetella’(Mesh), Limits ‘01 January 2001 to 01
August 2013’] initially yielded 1471 results, but only five
publications reported incidence of B. petrii in humans; as
referenced above, three were case reports detailing clinical
symptoms associated with colonization (mandibular
osteomyelitis, chronic suppurative mastoiditis and an
acute infective exacerbation in a patient with a background
history of bronchiectasis) and two described methods of
isolating B. petrii from biological material.
In a previous study describing a patient with bronchiec-
tasis, B. petrii colonization lasting 13 months was
described as ‘long-lasting persistence’ (Le Coustumier et
al., 2011). In this study, we determined that duration of
colonization was between 8 and 35 months (a conclusion
based on PFGE profiling of isolated cultures rather than
comparison of each individual isolate with type strains),
and therefore was ‘long lasting’ but, due to recurrent
isolation despite repeated antimicrobial therapy, ‘recalci-
trant’ may be a more accurate term.
As with previous studies in which varying media were used
to culture B. petrii [fastidious anaerobe agar, Columbia
blood agar and MacConkey agar, horse blood, and
MacConkey and chocolate agar, as well as chocolate
PolyViteX, bromocresol purple and selective Haemophilus
agar (chocolate bacitracin); Stark et al., 2007], we found
that conventional microbiology techniques for identifica-
tion of B. petrii were unsuccessful and, indeed, often
misidentified the bacterium. However, molecular techni-
ques were effective.
In performing analyses for this study, we determined that,
from the adult CF patient population of 45 in Limerick, B.
petrii had colonized four patients (9 %). In contrast, none
of the 81 paediatric CF patients have been positive for B.
petrii, supporting the rationale that B. petrii, as an
environmental isolate, is emerging as an opportunistic
pathogen in patients with altered microflora due to
repeated, long-term exposure to antimicrobials (Zelazny
et al., 2013; Gross et al., 2008; von Wintzingerode et al.,
2002). However, the concept of emergent pathogens
should be considered in the context of better diagnostic
techniques and their influence on reported incidences.
In the four patients described here, B. petrii was
monomicrobial in only 16 % of positive samples, and
was found in conjunction with known pathogens in 68 %
of microbiological processing of sputa (e.g. P. aeruginosa
was detected in 30 %) and with non-pathogens
(Alcaligenes faecalis, Aspergillus fumigatus and C. metalli-
durans) in 10 %. Owing to the complex nature of CF
infections with the tendency of bacteria to co-exist as
biofilms within the lungs of CF patients, as well as varying
baselines of patient health, it is difficult to definitively state
the clinical significance of B. petrii in this case series.
However, two of the patients were symptomatic during
monomicrobial colonization by B. petrii, and one patient
was symptomatic during co-colonization by B. petrii and
Aspergillus fumigatus, a species with limited evidence of
invasive pathogenicity in CF. Conversely, however, patient
B experienced persistent asymptomatic colonization for
22 months, and the presence of B. petrii could not be
correlated with variations in lung function for any of the
four patients.
The cases reported here illustrate the recalcitrance of B.
petrii and its ability to recur. Previously published papers,
describing clinical involvement of B. petrii, have failed to
identify the sources of infection, and no guidelines exist as
yet regarding the antimicrobial susceptibility of B. petrii.
Antimicrobial MICs in the literature are the only guidance
for effective treatment of B. petrii, and so this study brings
together for the first time (Table 2) MICs for the first B.
petrii environmental isolate and available information for
all published clinical isolates and the multiple isolates of
the Limerick strain from this study (completed following
Clinical and Laboratory Standards Institute guidelines). In
summary, susceptibility testing using disc diffusion tests
showed apparent sensitivity of B. petrii to erythromycin,
gentamicin, ceftriaxone and piperacillin/tazobactam, with
resistance to amoxicillin, co-amoxiclav, tetracycline, clin-
damycin, ciprofloxacin and metronidazole (Fry et al.,
2005). However, in vivo antimicrobial treatments did not
mirror results under laboratory conditions and, specifi-
cally, the VITEK2 Compact system has been criticized as
inappropriate for the susceptibility testing of Bordetella
species (Le Coustumier et al., 2011). In practice, clari-
thromycin has been used preferentially for B. petrii.
However, studies have shown resistance to this antibiotic
in vitro, and when administered to patients for differing
durations – 6 weeks (Fry et al., 2005) and 8 weeks (Stark et
al., 2007) – improvement of symptoms was observed but
in conjunction with the emergence of resistance. Indeed,
positive patient outcome was subsequently attributed to
ancillary treatment (Fry et al., 2005). Amoxicillin and
metronidazole have been administered with no resolution
of symptoms (Fry et al., 2005), whilst co-amoxiclav has
improved symptoms but not eradicated B. petrii coloniza-
tion (Le Coustumier et al., 2011). In the patients reported
here, B. petrii was sensitive to piperacillin/tazobactam and
minocycline but resistant to erythromycin and aztreonam
(Table 2). Worryingly, the Limerick B. petrii isolate was
resistant to antimicrobials in the macrolide, most of the b-
lactam and the fluoroquinolone groups, and can therefore
be considered multidrug-resistant.
Overall, this paper advances our knowledge surrounding B.
petrii in the clinical setting, and represents the first report
to our knowledge of multiple patients colonized by a single
B. petrii strain, highlights problematic B. petrii identifica-
tion and indicates that colonization may be under-
estimated in the CF population. Furthermore, B. petrii
A. Carleton and others
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was present in all cases of CF exacerbation in the patients
colonized, and was found to be multidrug-resistant, with
piperacillin/tazobactam being the only effective common
antimicrobial therapy.
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